Katelyn T. Byrne

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

Jinyang Li, Katelyn T. Byrne, Fangxue Yan et al. · Immunity · 2018 · 721 citations · Full text

Immune Evasion, Tumor Immunology, Cancer Immunosurveillance +11

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma

Rafael Winograd, Katelyn T. Byrne, Rebecca A. Evans et al. · Cancer Immunology Research · 2015 · 457 citations · Full text

Immune Checkpoint Molecules, Immunology, Immune Regulation +21

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Lacey Padrón, Deena M. Maurer, Mark H. O’Hara et al. · Nature Medicine · 2022 · 316 citations · Full text

Randomized Phase 2, Pancreatic Cancer, Gastrointestinal Oncology +13

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

Mark H. O’Hara, Eileen M. O’Reilly, Gauri R. Varadhachary et al. · The Lancet Oncology · 2020 · 286 citations

Phase 1B, Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma +7

CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer

Katelyn T. Byrne, Robert H. Vonderheide · Cell Reports · 2016 · 278 citations · Full text